Hyperfibrinogenemia predicts long-term risk of death after ischemic stroke

Marta Swarowska · Agnieszka Polczak · Joanna Pera · Aleksandra Klimkowicz-Mrowiec · Agnieszka Slowik · Tomasz Dziedzic

Published online: 9 August 2014
© The Author(s) 2014. This article is published with open access at Springerlink.com

Abstract In stroke patients higher levels of plasma fibrinogen are associated with increased risk of unfavourable functional outcome and short-term mortality. The aim of our study was to determine the relationship between plasma fibrinogen level and long-term risk of death in ischemic stroke patients. Seven hundred thirty six patients (median age 71; 47.1 % men) admitted to the stroke unit within 24 h after stroke were included. Plasma fibrinogen level was measured on day 1 of hospitalisation. Hyperfibrinogenemia was defined as plasma fibrinogen concentration \(>3.5 \text{ g/L}\). The maximal follow-up period was 84 months. Hyperfibrinogenemia was found in 25.0 % of patients. On multivariate logistic regression analysis, after adjustment for age, stroke severity, atrial fibrillation, smoking, white blood cell count, fever, in-hospital pneumonia and hyperglycemia, hyperfibrinogenemia was associated with increased case fatality (HR 1.71, 95 % CI 1.29–2.26, \(P<0.01\)). Hyperfibrinogenemia predicts the long-term risk of death in ischemic stroke patients.

Keywords Stroke · Fibrinogen · Mortality · Outcome

Introduction

Fibrinogen is a coagulation factor, a major determinant of plasma viscosity and key factor for platelet activation. It belongs also to acute phase proteins. A numerous studies have demonstrated that plasma fibrinogen level is consistently and independently from traditional risk factors related to cardiovascular risk [1]. Fibrinogen has emerged as an important additional marker for stratification of cardiovascular event risk. The analysis compromising participant data from 52 prospective studies showed that the assessment of fibrinogen in people at intermediate risk for cardiovascular event could help prevent one additional event over a period of 10 years for every 400–500 people so screened [2].

In stroke patients higher levels of plasma fibrinogen are associated with increased risk of unfavourable functional outcome [3–8], short-term mortality [3–5, 9] and new cardiovascular events [10–12].

Much less is known about the association between hyperfibrinogenemia and long-term mortality after stroke. In one study, the ischemic stroke patients with hyperfibrinogenemia were more likely to die after 12 months than those with normal plasma fibrinogen and the increased fibrinogen concentration was an independent predictor of death [3]. From clinical point of view it is important to determine if increased plasma fibrinogen level is related to long-term mortality after stroke. First, fibrinogen could serve as a biomarker to identify patients who are at risk of death. Such patients may require careful monitoring and more aggressive secondary prevention. Second, fibrinogen can be considered as potential therapeutic target, because its level could be reduced by smoking cessation, diet, physical activity and some drugs.

The aim of our study was to determine the relationship between plasma fibrinogen level and long-term risk of death in ischemic stroke patients.

Materials and methods

We retrospectively analysed the prospectively collected data on prognosis in stroke patients. The consecutive
patients with first-ever ischemic stroke admitted to our stroke unit within 24 h after stroke onset were eligible for the study. The patients were recruited to the study between November 2004 and October 2007. The only exclusion criterion was the lack of patient’s consent for participation in the study.

All patients underwent head CT scan within 24 h after stroke onset. Stroke severity on admission was assessed using National Institute of Health Stroke Scale (NIHSS).

Arterial hypertension was diagnosed when its presence was documented in medical records or when at least two readings of blood pressure were ≥140 mmHg (systolic) or ≥90 mmHg (diastolic) after the acute phase of stroke. The diagnosis of diabetes mellitus was made when (1) the patient had the recognized diabetes mellitus before stroke as written in medical records and/or took hypoglycemic drugs before stroke; (2) fasting plasma glucose measured on day 6–10 was ≥7.0 mmol/L or fasting plasma glucose was 6.1–6.9 mmol/L and 2 h plasma glucose was ≥11.1 mmol/L or oral glucose tolerance test. A patient was defined as a smoker if there was a history of cigarette smoking during the last 5 years.

Plasma fibrinogen level was determined on day 1 using modified Clauss method (Dade Behring, Marburg, Germany). Hyperfibrinogenemia was defined as plasma concentration >3.5 g/L.

The follow-up was up to 84 months with the minimal duration of 12 months. Information about death was taken from the town registry.

The study protocol was approved by the local Bioethics Committee and each participant gave the informed consent.

The χ² test was used to compare proportions and Mann–Whitney’s test to compare continuous variables between groups. Values of less than 0.05 were considerate to indicate statistical significance. Log-rank test was used to compare survival between the patients with hyperfibrinogenemia and those with normofibrinogenemia. The patients with hyperfibrinogenemia had shorter time of survival than those with normofibrinogenemia (P < 0.01, log-rank test).

Table 2 shows independent predictors of death on univariate analysis.

Hyperfibrinogenemia was associated with risk of death both on univariate (HR 1.62, 95 % CI 1.28–2.07, P < 0.01) and multivariate analysis (HR 1.71, 95 % CI 1.29–2.26, P < 0.01). Other independent predictors of death on multivariate analysis were: age (HR 1.03, 95 % CI 1.01–1.04, P < 0.01), NIHSS score (HR 1.08, 95 % CI 1.05–1.10, P < 0.01), atrial fibrillation (HR 1.62, 95 % CI 1.20–2.18, P < 0.01), white blood cell count count >10,000/μL (HR 1.32, 95 % CI 1.02–1.71, P = 0.03) and the body temperature >37.5 °C during first 48 h of stroke (HR 1.48, 95 % CI 1.13–1.92, P < 0.01).

**Discussion**

In our study hyperfibrinogenemia was associated with long-term risk of death after ischemic stroke and this relationship was independent from age, stroke severity, and selected inflammation-related variables (fever, leukocytosis, in-hospital pneumonia). New information provided by our study is that in relatively large cohort of unselected ischemic stroke patients hyperfibrinogenemia predicts mortality beyond 1 year.

The results of a few studies indicate that hyperfibrinogenemia observed in acute stroke persists even 1 year after the event. It suggests that the stimuli for fibrinogen synthesis are still active even months after cerebral infarction [13, 14]. Levels of fibrinogen are influenced by genotype and therefore persistent hyperfibrinogenemia could be related to variation in genomic sequences [15, 16]. Finally, the elevated levels of fibrinogen observed months after stroke might reflect pre-stroke hyperfibrinogenemia which is considered as a risk factor for stroke [17, 18].

Our findings should be interpreted in light of the results of the studies investigating the relationship between fibrinogen and mortality in non-stroke populations. In large individual participant meta-analysis, moderately strong association was found between plasma fibrinogen and the risk of vascular and non-vascular mortality in healthy middle age adults [18]. In EPIC-Norfolk study including 16,850 participants aged 40–79, fibrinogen level predicts long-term risk of death after adjustment of cardiovascular...
Higher fibrinogen concentration was also associated with increased risk of death in patients with unstable angina [20], diabetes mellitus [21] or renal failure [22, 23]. Taking together, these results suggest that plasma fibrinogen level is a non-specific marker of mortality and bring the causal link between hyperfibrinogenemia and increased risk of death in question.

### Table 1
The baseline characteristics of the patients with and those without hyperfibrinogenemia

| Risk Factor                              | Patients with normofibrinogenemia (N = 552) | Patients with hyperfibrinogenemia (N = 184) | P  |
|------------------------------------------|--------------------------------------------|---------------------------------------------|----|
| Age, median (IQ)                         | 70.0 (63.0–78.0)                           | 71.5 (62.0–81.0)                            | 0.32|
| Men, n (%)                               | 243 (44.0)                                 | 104 (56.5)                                 | <0.01|
| Hypertension, n (%)                      | 375 (67.9)                                 | 124 (67.4)                                 | 0.89|
| Diabetes mellitus, n (%)                 | 115 (20.8)                                 | 37 (20.1)                                  | 0.83|
| Previous myocardial infarction, n (%)    | 64 (11.6)                                  | 33 (17.9)                                  | 0.03|
| Atrial fibrillation, n (%)               | 127 (23.0)                                 | 30 (16.3)                                  | 0.05|
| Smoking, n (%)                           | 145 (26.3)                                 | 55 (29.9)                                  | 0.34|
| NIHSS score on admission, median (IQ)    | 11.0 (6.8–17.0)                            | 12.0 (8.0–17.0)                            | 0.18|
| Systolic blood pressure on admission (mmHg), median (IQ) | 160 (140–180)                             | 160 (140–180)                             | 0.83|
| Diastolic blood pressure on admission (mmHg), median (IQ) | 90 (80–100)                               | 90 (80–100)                               | 0.26|
| Glucose on admission >7.0 mmol/L, n (%)  | 224 (40.5)                                 | 78 (42.4)                                  | 0.65|
| Fasting glucose >6.1 mmol/L, n (%)       | 225 (40.8)                                 | 82 (44.6)                                  | 0.42|
| Total cholesterol (mmol/L), median (IQ)  | 5.3 (4.5–6.2)                              | 5.3 (4.5–6.4)                              | 0.93|
| Body temperature >37.5 °C during first 48 h, n (%) | 122 (22.1)                                | 57 (30.9)                                  | 0.02|
| WBC count >10 000/µL, n (%)              | 150 (27.2)                                 | 77 (41.8)                                  | <0.01|
| In-hospital pneumonia, n (%)             | 58 (10.5)                                  | 17 (9.2)                                   | 0.62|

### Table 2
The predictors of death on univariate analysis

| Risk Factor                              | HR, 95 %CI                     | P value |
|------------------------------------------|--------------------------------|---------|
| Age (increase per unit)                  | 1.03 (1.02–1.04)               | <0.01   |
| NIHSS score on admission (increase per unit) | 1.09 (1.07–1.11)             | <0.01   |
| Atrial fibrillation                      | 1.75 (1.37–2.25)               | <0.01   |
| Smoking                                  | 0.69 (0.54–0.89)               | <0.01   |
| WBC count >10 000/µL                    | 1.46 (1.17–1.83)               | <0.01   |
| Body temperature >37.5 °C during first 48 h | 2.03 (1.60–2.58)             | <0.01   |
| In-hospital pneumonia                    | 2.53 (1.90–3.37)               | <0.01   |
| Hyperfibrinogenemia                     | 1.62 (1.28–2.07)               | <0.01   |
| Fasting glucose >6.1 mmol/L             | 1.73 (1.38–2.18)               | <0.01   |

risk factors [19]. Higher fibrinogen concentration was also associated with increased risk of death in patients with unstable angina [20], diabetes mellitus [21] or renal failure [22, 23]. Taking together, these results suggest that plasma fibrinogen level is a non-specific marker of mortality and bring the causal link between hyperfibrinogenemia and increased risk of death in question.
It remains unclear if hyperfibrinogenemia in stroke patients is only a marker of mortality or a real culprit. The assessment of any causal relationship of fibrinogen level with mortality in stroke patients will require randomized trials of selective fibrinogen-lowering drugs or Mendelian randomization studies assessing genetic determinants of fibrinogen level.

Fibrinogen levels can be reduced by lifestyle modification (for example, smoking cessation, regular exercises, diet, etc.) or medication (for example, fibrates). Taking into account the persistence of hyperfibrinogenemia after stroke and its relationship to death, any interventions aimed to decrease post-stroke mortality by lowering fibrinogen levels should be long-lasting.

In conclusion, hyperfibrinogenemia predicts the long-term risk of death in ischemic stroke patients.

Acknowledgment The authors declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References
1. Koenig W (2003) Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost 89:601–609
2. Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Peto R, Stevens G, Graham I, Welton NJ, Law MR, Seshadri S, steering committee (2012) Risk of cardiovascular disease associated with C-reactive protein, fibrinogen and leukocyte count in men and women: the EPIC-Norfolk study. Eur J Epidemiol 27:207–220
3. Turaj W, Slowik A, Dziedzic T, Pulyk R, Adamski M, Strojny J, Szczudluk A (2006) Increased plasma fibrinogen predicts one-year mortality in patients with acute ischemic stroke. J Neurol Sci 246:13–19
4. González-Concejero R, Fernández-Cadenas I, Iniesta JA, Martí-Fabregas I, Obach V, Alvarez-Sahín J, Vicente C, Corral J, Montaner J (2006) Role of fibrinogen levels and factor XIII V34L polymorphism in thrombolytic therapy in stroke patients. Stroke 37:2288–2293
5. Tanne D, Macko RF, Lin Y, Tilley BC, Levine SR, NINDS rTPA Stroke Study Group (2006) Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke. Stroke 37:1798–1804
6. del Zoppo GJ, Levy DE, Wasiewski WW, Pancioli AM, Demchuk AM, Tramell J, Damerauchalk BM, Kaste M, Albers GW, Ringelstein EB (2009) Hyperfibrinogenemia and functional outcome from acute ischemic stroke. Stroke 40:1687–1691
7. Whiteley W, Jackson C, Lewis S, Lowe G, Rumley A, Sande-
cock P, Wardlaw J, Dennis M, Sudlow C (2009) Inflammatory markers and poor outcome after stroke: a prospective cohort study and systematic review of interleukin-6. PLoS Med 6:e1000145
8. van den Herik EG, Cheung EY, de Lau LM, den Hertog HM, Leebeek FW, Dippel DW, Koudstaal PJ, de Maat MP (2011) γ/total fibrinogen ratio is associated with short-term outcome in ischaemic stroke. Thromb Haemost 105:430–434
9. Rallidis LS, Vikelis M, Panagiotakos DB, Liakos GK, Krania E, Kremastinos DT (2008) Usefulness of inflammatory and haemostatic markers to predict short-term risk for death in middle-aged ischaemic stroke patients. Acta Neurol Scand 117:415–420
10. Resch KL, Ernst E, Matrai A, Paulsen HF (1992) Fibrinogen and viscosity as risk factors for subsequent cardiovascular events in stroke survivors. Ann Intern Med 117:371–375
11. Woodward M, Lowe GD, Campbell DJ, Colman S, Rumley A, Chalmers J, Neal BC, Patel A, Jenkins AJ, Kemp BE, MacMahon SW (2005) Associations of inflammatory and haemostatic variables with the risk of recurrent stroke. Stroke 36:2143–2147
12. Di Napoli M, Papa F, Villa Pini Stroke Data Bank Investigators (2002) Inflammation, hemostatic markers, and anti-thrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients. Stroke 33:1763–1771
13. Beamer NB, Coull BM, Clark WM, Birley DP, Wynn M, Sexton G (1998) Persistent inflammatory response in stroke survivors. Neurology 50:1722–1728
14. Shenhari-Tsarfaty S, Ben Assyayeg E, Boiva I, Shopin L, Cohen M, Berliner S, Shapiro I, Bornstein NM (2008) Persistent hyperfi-
brinogenemia in acute ischemic stroke / transient ischemic attack (TIA). Thromb Haemost 99:169–173
15. Tousoulis D, Papageorgiou N, Androulakis E, Bratsioulis A, Antoniades C, Stefanadis C (2011) Fibrinogen and cardiovascular disease: genetics and biomarkers. Blood Rev 25:239–245
16. de Maat MP, Verschuur M (2005) Fibrinogen heterogeneity: inherited and noninherited. Curr Opin Hematol 12:377–383
17. Rotthuyl P, Howard SC, Power DA, Guttikov SA, Algra A, van Ginj L, Clark TG, Murphy MF, Warlow CP (2004) Fibrino-
gen concentration and risk of ischemic stroke and acute coronary events in 5113 patients with transient ischemic attack and minor ischemic stroke. Stroke 35:2300–2305
18. Fibrinogen Studies Collaboration (2005) Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: a individual participant meta-analysis. JAMA 294:1799–1809
19. Ahmadi-Abhari S, Luben RN, Wareham NJ, Khaw KT (2013) Seventeen year risk of all-cause and cause-specific mortality associated with C-reactive protein, fibrinogen and leukocyte count in men and women: the EPIC-Norfolk study. Eur J Epidemiol 28:541–550
20. Toss H, Lindahl B, Siegbahn A, Wallentin L (1997) Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Framin during Instability in Coronary Artery Disease. Circulation 96:4204–4210
21. Bruno G, Merletti F, Biggeri A, Bargergro G, Ferrero S, Pagano G, Cavallo-Perin P, Casale Monferrato Study (2005) Fibrinogen and AER are major independent predictors of 11-year cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetologia 48:427–434

© Springer
22. Zoccali C, Mallamaci F, Tripepi G, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Stancanelli B, Nicocia G, Buemi M (2003) Fibrinogen, mortality and incident cardiovascular complications in end-stage renal failure. J Intern Med 254:132–139

23. Goicoechea M, de Vinuesa SG, Gómez-Campderí F, Aragoncillo I, Verdalles U, Mosse A, Luño J (2008) Serum fibrinogen levels are an independent predictor of mortality in patients with chronic kidney disease (CKD) stages 3 and 4. Kidney Int Suppl. 111:S67–S70